☆ 4.7 Letter

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

ANNALS OF ONCOLOGY (2020)

期刊

ANNALS OF ONCOLOGY

卷 31, 期 10, 页码 1415-1416

出版社

ELSEVIER

DOI: 10.1016/j.annonc.2020.06.005

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review

Orazio Caffo, Marco Messina, Antonello Veccia, Stefania Kinspergher, Francesca Maines, Carlo Messina

Summary: Real-world data suggest a possible interplay between ADT and susceptibility to SARS-CoV-2 infection, but current evidence is conflicting. Larger and more precise studies are needed to determine the true effect of ADT in preventing or reducing the severity of SARS-CoV-2 infection.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy

Rolf Gedeborg, Stacy Loeb, Johan Styrke, Ritva Kiiski-Berggren, Hans Garmo, Par Stattin

Summary: This study analyzed data from the Prostate Cancer data Base Sweden (PCBaSe) and found that men undergoing androgen deprivation therapy (ADT) had increased risks of testing positive for COVID-19 infection and subsequent hospital admission/death. However, after adjusting for age, comorbidity, and prostate cancer risk category, these associations were attenuated. The findings suggest that the increased risks may be attributed to confounding factors such as old age, cancer-associated morbidity, and other comorbidities rather than a direct effect of the therapy.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Review Medicine, General & Internal

Relationship Between Androgen Deprivation Therapy for Prostate Cancer and Risk of SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

Do Kyung Kim, Jae Joon Park, Won Jae Yang, Seung Whan Doo, Jae Heon Kim

Summary: This study aimed to investigate the relationship between androgen deprivation therapy (ADT) and the severity of COVID-19 in patients with prostate cancer. The results showed no significant difference in SARS-CoV-2 positivity, hospitalization, ICU admission, or death between patients treated with ADT and those who were not.

JOURNAL OF KOREAN MEDICAL SCIENCE (2022)

添加到收藏夹

Review Urology & Nephrology

Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis

Reza Sari Motlagh, Mohammad Abufaraj, Pierre I. Karakiewicz, Pawel Rajwa, Keiichiro Mori, Dong-Ho Mun, Shahrokh F. Shariat

Summary: The study aimed to evaluate the risk of SARS-CoV-2 infection and disease severity in prostate cancer patients undergoing androgen deprivation therapy (ADT). The results showed that PCa patients can safely undergo ADT during the COVID-19 pandemic without worsening the risk and trajectory of COVID-19.

WORLD JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Oncology

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Fatima Karzai, Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino, Stephanie A. Harmon, David J. VanderWeele, Lisa M. Cordes, Nicole Carrabba, John R. Bright, Nicolas T. Terrigino, Guinevere Chun, Marijo Bilusic, Anna Couvillon, Amy Hankin, Monique N. Williams, Rosina T. Lis, Huihui Ye, Peter L. Choyke, James L. Gulley, Adam G. Sowalsky, Baris Turkbey, Peter A. Pinto, William L. Dahut

Summary: For patients with localized intermediate- or high-risk prostate cancer, baseline mpMRI can help predict pathologic response, with low relative tumor burden at initial scan being most predictive of minimal residual disease or pathologic complete response. Tailoring patient selection based on these metrics may lead to improved outcomes in high-risk disease.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Multidisciplinary Sciences

Testosterone suppression combined with high dose estrogen as potential treatment of SARS-CoV-2. A mini review

Herjan J. T. Coelingh Bennink, Jan F. M. Egberts, Frans M. J. Debruyne

Summary: Compared to females, males are more susceptible to and have higher mortality rates from COVID-19. Testosterone and estrogen play different roles in the immune system, and regulating their levels can decrease viral entry into cells.

HELIYON (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients

Estibaliz Jimenez-Alcaide, Clara Garcia-Fuentes, Virginia Hernandez, Enrique De la Pena, Elia Perez-Fernandez, Alejandro Castro, Begona Caballero-Perea, Ana Guijarro, Carlos Llorente

Summary: This study confirms that COVID-19 is more severe in men. However, the use of androgen deprivation therapy (ADT) in patients with prostate cancer (PC) was not shown to prevent the risk of severe COVID-19.

PROSTATE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection

Sabina Davidsson, Anna Messing Eriksson, Ruzan Udumyan, Per Swanholm, Maria Lewin Lundh, Carolina Widing, Christina Lindlof, Jonna Fridfeldt, Sven-Olof Andersson, Katja Fall

Summary: Studies have shown inconsistent results regarding the association between androgen deprivation therapy (ADT) and the risk or severity of SARS-CoV-2 infection in prostate cancer patients. This study found no differences in symptoms or risk of SARS-CoV-2 infection between patients with and without ADT after adjusting for potential confounders.

PROSTATE (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Characterization and antiviral susceptibility ofSARS-CoV-2 Omicron BA.2

Ryuta Uraki, Maki Kiso, Shun Iida, Masaki Imai, Emi Takashita, Makoto Kuroda, Peter J. Halfmann, Samantha Loeber, Tadashi Maemura, Seiya Yamayoshi, Seiichiro Fujisaki, Zhongde Wang, Mutsumi Ito, Michiko Ujie, Kiyoko Iwatsuki-Horimoto, Yuri Furusawa, Ryan Wright, Zhenlu Chong, Seiya Ozono, Atsuhiro Yasuhara, Hiroshi Ueki, Yuko Sakai-Tagawa, Rong Li, Yanan Liu, Deanna Larson, Michiko Koga, Takeya Tsutsumi, Eisuke Adachi, Makoto Saito, Shinya Yamamoto, Masao Hagihara, Keiko Mitamura, Tetsuro Sato, Masayuki Hojo, Shin-ichiro Hattori, Kenji Maeda, Riccardo Valdez, Moe Okuda, Jurika Murakami, Calvin Duong, Sucheta Godbole, Daniel C. Douek, Ken Maeda, Shinji Watanabe, Aubree Gordon, Norio Ohmagari, Hiroshi Yotsuyanagi, Michael S. Diamond, Hideki Hasegawa, Hiroaki Mitsuya, Tadaki Suzuki, Yoshihiro Kawaoka

Summary: The replicative ability and pathogenicity of Omicron BA.2 variant is similar to that of BA.1 in rodents, but it shows less pathogenicity compared to early SARS-CoV-2 strains. There is a marked reduction in the neutralizing activity of plasma from individuals who had recovered from COVID-19 and vaccine recipients against BA.2 variant.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke, William Cross, Robert J. Jones, Christopher C. Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L. Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J. Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M. O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S. de Bono, David P. Dearnaley, Malcolm D. Mason, Duncan Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise C. Brown, Mahesh K. B. Parmar, Nicholas D. James

Summary: The combination therapy of abiraterone acetate with prednisolone showed significantly higher rates of metastasis-free survival compared with ADT alone in men with high-risk non-metastatic prostate cancer. This combination therapy may be considered a new standard treatment for this patient population.

LANCET (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

The effect of social deprivation on the dynamic of SARS-CoV-2 infection in France: a population-based analysis

Stephanie Vandentorren, Sabira Smaili, Edouard Chatignoux, Marine Maurel, Caroline Alleaume, Lola Neufcourt, Michelle Kelly-Irving, Cyrille Delpierre

Summary: This study examined the association between area-based deprivation and SARS-CoV-2 incidence, positivity, and testing rates in France. The findings showed that the most deprived areas had higher incidence and positivity rates, while testing rates were lower. These results suggest that there are structural barriers to healthcare access for deprived populations in France.

LANCET PUBLIC HEALTH (2022)

添加到收藏夹

Article Oncology

Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death

Derya Tilki, Ming-Hui Chen, Jing Wu, Hartwig Huland, Markus Graefen, Thomas Wiegel, Dirk Boehmer, Osama Mohamad, Janet E. Cowan, Felix Y. Feng, Peter R. Carroll, Bruce J. Trock, Alan W. Partin, Anthony D'Amico

Summary: The study found that adjuvant radiation therapy compared to early salvage radiation therapy significantly reduces all-cause mortality in men with adverse pathology, such as positive pelvic lymph nodes or high Gleason score prostate cancer.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study

Irving Kaplan, Glenn J. Bubley, Rupal S. Bhatt, Mary-Ellen Taplin, Shanna Dowling, Kathleen Mahoney, E. Werner, Paul Nguyen

Summary: Combining enzalutamide monotherapy with radiation therapy is effective for intermediate-risk prostate cancer, with high PSA response rates and fewer side effects, predominantly hypertension and gynecomastia.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Medicine, General & Internal

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone

Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh

Summary: This study investigated the differences in outcomes between African American and non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC) who received first-line abiraterone therapy. The results showed that African American men had a higher overall survival when receiving first-line abiraterone compared to non-Hispanic White men. However, there was a difference in outcomes between the two groups for first-line enzalutamide treatment.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Oncology

Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial

Daniel E. Spratt, Vinnie Y. T. Liu, Jeff Michalski, Elai Davicioni, Alejandro Berlin, Jeffry P. Simko, Jason A. Efstathiou, Phuoc T. Tran, Howard M. Sandler, William A. Hall, Darby J. S. Thompson, Matthew B. Parliament, Ian S. Dayes, Rohann Jonathan Mark Correa, John M. Robertson, Elizabeth M. Gore, Desiree E. Doncals, Eric Vigneault, Luis Souhami, Theodore G. Karrison, Felix Y. Feng

Summary: This study validates the prognostic and predictive value of a biopsy-based gene expression classifier (GC) in intermediate-risk prostate cancer, showing that GC can improve risk stratification and aid in treatment decision-making.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

添加到收藏夹

Article Oncology

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

Sebastiano Buti, Umberto Basso, Diana Giannarelli, Ugo De Giorgi, Marco Maruzzo, Roberto Iacovelli, Luca Galli, Camillo Porta, Francesco Carrozza, Giuseppe Procopio, Giuseppe Fonarini, Giovanni Lo Re, Matteo Santoni, Roberto Sabbatini, Antonio Cusmai, Paolo Andrea Zucali, Carlo Aschele, Editta Baldini, Elena Zafarana, Adolfo Favaretto, Silvana Leo, Alketa Hamzaj, Rosanna Mirabelli, Franco Nole', Silvia Zai, Claudio Chini, Cristina Masini, Sonia Fatigoni, Andrea Rocchi, Emiliano Tamburini, Alessio Cortellini, Melissa Bersanelli

Summary: We developed a drug-based score to predict prognosis and treatment response in advanced cancer patients receiving immune checkpoint inhibitors (ICIs), and validated its value in a population of metastatic renal cell carcinoma patients treated with ipilimumab plus nivolumab. The model considers the use of certain drugs before immunotherapy initiation and demonstrated significant and clinically meaningful predictions for overall survival and progression-free survival. Further development will involve analyzing the gut microbiome and its link to drug exposure and immune sensitivity.

JOURNAL OF IMMUNOTHERAPY (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q. S. Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini

Summary: This study aimed to evaluate a prognostic model based on the time of metastatic disease presentation and disease burden for mCRPC patients receiving AA or Enza as first-line treatment. The analysis showed that patients with low disease burden had improved overall survival compared to those with high disease burden, regardless of the time of disease presentation.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study

Matteo Bauckneht, Cecilia Marini, Vanessa Cossu, Cristina Campi, Mattia Riondato, Silvia Bruno, Anna Maria Orengo, Francesca Vitale, Sonia Carta, Silvia Chiola, Sabrina Chiesa, Alberto Miceli, Francesca D'Amico, Giuseppe Fornarini, Carlo Terrone, Michele Piana, Silvia Morbelli, Alessio Signori, Paola Barboro, Gianmario Sambuceti

Summary: This study investigated the independent and additive prognostic value of PSMA and FDG gene expression in risk-stratification of prostate cancer (PCa). Machine learning analysis identified a predictive functional network involving glucose metabolism-related genes. Cellular experiments showed that increased proliferation and migration of PCa cells were associated with enhanced FDG uptake and decreased PSMA retention, indicating the prognostic value of FDG PET imaging.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

添加到收藏夹

Review Urology & Nephrology

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Alessandro Rizzo, Matteo Santoni, Francesco Massari

Summary: The approval of immunotherapy agents has revolutionized the treatment of renal cell carcinoma, but biomarkers to predict immunotherapy response are urgently needed. Currently available prognostic models are based on clinical and laboratory factors, but new molecular features might improve disease prediction. Effective markers for guiding therapeutic strategies still need validation.

NATURE REVIEWS UROLOGY (2023)

添加到收藏夹

Article Oncology

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Alessia Salfi, Thomas Buettner, Ugo De Giorgi, Ravindran Kanesvaran, Ondrej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T. Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R. Matrana, Renate Pichler, Carlo Cattrini, Tomas Buechler, Emmanuel Seront, Fabio Calabro, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Roubini Zakopoulou, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Ilaria Zampiva, Carlo Messina, Zsofia Kueronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Ilaria Catalini, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Mimma Rizzo, Camillo Porta

Summary: Obesity is associated with improved response to immunotherapy in metastatic renal cell carcinoma, but its prognostic significance and association vary across subgroups.

CLINICAL GENITOURINARY CANCER (2023)

添加到收藏夹

Article Cell Biology

FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type

Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Giorgia Di Filippo, Eugenia Franchini, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, Michelangelo Fiorentino

Summary: The study aimed to assess the staining pattern of FoxA2 in different patterns of yolk sac tumour postpubertal-type (YSTpt) and other germ cell tumours of the testis (GCTT), comparing it with glypican-3 (GPC3) and α-fetoprotein (AFP). The results showed that FoxA2 is a highly sensitive and specific biomarker for YSTpt, especially in rare and difficult-to-diagnose histological patterns, and it is superior to GPC3 and AFP. However, mature glands of teratoma postpubertal-type (Tpt) could be a potential diagnostic pitfall.

HISTOPATHOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

Federica Borea, Marika A. Franczak, Maria Garcia, Matteo Perrino, Nadia Cordua, Ryszard T. Smolenski, Godefridus J. Peters, Rafal Dziadziuszko, Armando Santoro, Paolo A. Zucali, Elisa Giovannetti

Summary: Malignant Pleural Mesothelioma (MPM) is a rare neoplasm that is usually diagnosed at an advanced stage and requires systemic treatment due to its ineligibility for radical surgery. Chemotherapy has been the standard treatment for 20 years until immune checkpoint inhibitors were introduced. However, the prognosis remains poor, and targeted therapies for MPM have mostly failed in clinical trials. This review aims to explore the potential reasons for treatment failures and determine the need for further research in this area.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Oncology

Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer

Malvina Cremante, Silvia Puglisi, Annalice Gandini, Antonio Guadagno, Fabio Catalano, Alessandra Damassi, Veronica Murianni, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Sebastiano Buti, Sara Elena Rebuzzi, Pasquale Rescigno, Giuseppe Fornarini

Summary: Apalutamide, an oral selective androgen receptor inhibitor, is approved by FDA for the treatment of high-risk non-metastatic castration-resistant prostate cancer (M0 CRPC) and metastatic castration-sensitive prostate cancer (mHSPC). This case report describes a rare skin adverse event, lichenoid reaction, induced by Apalutamide. A multidisciplinary approach confirmed the correlation between lichenoid reaction and the drug.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2023)

添加到收藏夹

Article Oncology

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study

Sara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, Valerio Gaetano Vellone, Alessio Signori, Fabio Catalano, Alessandra Damassi, Gabriele Gaggero, Pasquale Rescigno, Marco Maruzzo, Sara Merler, Francesca Vignani, Alessia Cavo, Umberto Basso, Michele Milella, Olimpia Panepinto, Manlio Mencoboni, Marta Sbaraglia, Angelo Paolo Dei Tos, Veronica Murianni, Malvina Cremante, Miguel Angel Llaja Obispo, Michele Maffezzoli, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini

Summary: This study identified differential immunohistochemical patterns in the tumors of patients who responded and did not respond to nivolumab, an immunotherapy. Tumors in responders showed poor presence of CD4+ immune cells, high expression of CD56 on tumor cells, and high expression of phosphorylated mTOR protein. Further investigation with genomic analysis is planned to examine the prognostic role of the tumor microenvironment.

CANCERS (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study

Maria Silvia De Feo, Viviana Frantellizzi, Matteo Bauckneht, Alessio Farcomeni, Luca Filippi, Elisa Lodi Rizzini, Valentina Lavelli, Maria Lina Stazza, Tania Di Raimondo, Giuseppe Fornarini, Sara Elena Rebuzzi, Mammini Filippo, Paolo Mammucci, Andrea Marongiu, Fabio Monari, Giuseppe Rubini, Angela Spanu, Giuseppe De Vincentis

Summary: This multicenter study aimed to assess the impact of baseline bone scan index (BSI) on overall survival (OS) in mCRPC patients treated with (RaCl2)-Ra-223. The results showed that baseline BSI significantly predicts OS in mCRPC treated with (RaCl2)-Ra-223.

BIOMEDICINES (2023)

添加到收藏夹

Review Chemistry, Medicinal

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics

Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J. Adashek

Summary: With the rise of precision medicine, the field of oncology has undergone significant changes due to the discovery of druggable genes or immune targets through next-generation sequencing. Biomarker-based treatments are emerging, and there are currently six tissue-agnostic therapies approved by the FDA.

PHARMACEUTICALS (2023)

添加到收藏夹

Article Oncology

The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

Emilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, Ugo De Giorgi, Marco Maruzzo, Sara Elena Rebuzzi, Marika Cinausero, Lucia Fratino, Helga Lipari, Teresa Gamba, Davide Bimbatti, Arianna Dri, Paola Ermacora, Francesca Vignani, Umberto Basso, Sebastiano Buti, Annalice Gandini, Malvina Cremante, Giuseppe Fornarini, Pasquale Rescigno, Giuseppe Luigi Banna

Summary: This study aimed to assess the characteristics of caregivers and the impact of their presence or absence on the clinical outcomes of older mCRPC patients treated with ABI or ENZ. The research found a detrimental effect of caregivers in managing older mCRPC patients, especially those identified as frail by the geriatric G8 screening score. Further research is needed to identify and address patients' vulnerability areas, which could have a detrimental effect on prognosis.

SUPPORTIVE CARE IN CANCER (2023)

添加到收藏夹

Article Oncology

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Mimma Rizzo, Luca Galli, Thomas Buettner, Ugo De Giorgi, Ravindran Kanesvaran, Ondrej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T. Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R. Matrana, Renate Pichler, Carlo Cattrini, Tomas Buechler, Emmanuel Seront, Fabio Calabro, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Aristotelis Bamias, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Sara Merler, Carlo Messina, Zsofia Kueronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Camillo Porta

Summary: The ARON-1 study collected real-world data on the use of immuno-combination therapies as first-line treatment for mRCC patients globally. The study showed that immuno-combination therapies are effective in the real-world context of mRCC, with longer survival observed in patients treated with IO + TKI combinations compared to IO + IO combinations in the intermediate/poor risk population.

TARGETED ONCOLOGY (2023)

添加到收藏夹

Review Pathology

Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT

Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Alessia Grillini, Eugenia Franchini, Marco Grillini, Riccardo Schiavina, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Lorenzo Bianchi, Matteo Droghetti, Thais Maloberti, Giovanni Tallini, Maurizio Colecchia, Andres Martin Acosta, Joao Lobo, Kiril Trpkov, Michelangelo Fiorentino, Dario de Biase

Summary: The 2022 WHO classification introduced new kidney entities with specific mutational backgrounds. Molecular techniques such as next-generation sequencing (NGS) are commonly used for evaluation. Our study focused on low-grade oncocytic tumors (LOT) of the kidney and found a strong association with mutations in the mTOR pathway.

VIRCHOWS ARCHIV (2023)

添加到收藏夹

Editorial Material Medicine, General & Internal

Cardiac Metastasis from Prostate Cancer: A Case Study Underlying the Crucial Role of the PSMA PET/CT

Annalice Gandini, Matteo Bauckneht, Luca Sofia, Laura Tomasello, Giuseppe Fornarini, Elisa Zanardi

Summary: Prostate cancer remains a major global health issue, and the introduction of PSMA PET/CT has greatly enhanced its diagnostic capabilities. This case study highlights the sensitivity of PSMA PET/CT in detecting metastatic prostate cancer, including a rare intra-atrial metastasis. It emphasizes the importance of next-generation imaging techniques in advancing our understanding of prostate cancer metastasis.

DIAGNOSTICS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.